Chemotherapy-induced pneumonitis associated with transient CA 15-3 elevation

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Hypersensitivity pneumonitis is a known risk of gemcitabine and paclitaxel chemotherapy.
• Diagnosis typically relies on imaging and bronchoscopy, lacking specific serological markers.
• Previous studies noted CA 15-3 elevation in collagen disease-related interstitial pneumonitis.

Observation:

• A 74-year-old patient with metastatic schwannoma developed drug-induced pneumonitis during gemcitabine and paclitaxel treatment.
• The patient experienced transient elevation of the tumor marker CA 15-3 concurrently with pneumonitis.
• Steroid treatment led to clinical and radiological improvement, with CA 15-3 normalization.

Findings:

• This case report documents the first instance of CA 15-3 elevation in drug-induced hypersensitivity pneumonitis.
• The CA 15-3 levels correlated with the presence and resolution of pneumonitis.

Implications:

• Blood CA 15-3 levels may serve as a potential biomarker for monitoring drug-induced pneumonitis.
• This finding could lead to earlier diagnosis and more effective management of chemotherapy-related lung injury.
• Further research is warranted to validate CA 15-3 as a reliable marker for drug-induced pneumonitis.